AbbVie sheds $38bn in value after failing schizophrenia drug trials
Portfolio Pulse from
AbbVie Inc has lost $38 billion in market value following the failure of its Phase 2 trials for the emraclidine schizophrenia treatment, which did not meet primary endpoint objectives.
November 11, 2024 | 4:15 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
AbbVie Inc's market value dropped by $38 billion after its emraclidine schizophrenia drug failed Phase 2 trials, not meeting primary endpoint objectives.
The failure of the emraclidine drug in Phase 2 trials is a significant setback for AbbVie, leading to a substantial $38 billion loss in market value. This indicates a negative short-term impact on the stock price as investors react to the failed trial results.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100